We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Insmed Inc. (NASDAQ:INSM) is one of the best-performing stocks on Thursday. Insmed rallied for a fourth straight day to reach a new all-time high, as investors took heart from a highly optimistic business outlook for the full-year period, despite widening its net loss in the third quarter. At intra-day trading, the stock soared to its highest 52-week price of $194.70 before trimming a few cents to end the day just up by 16.33 perc ...

Key Takeaways Insmed posted a Q3 loss of $1.75 per share, missing estimates despite higher revenue.Brinsupri added $28.1M in its first quarter of sales, driving strong investor optimism.Revenue rose 52% to $142.3M on growth in Arikayce and the successful Brinsupri launch.Insmed (INSM) reported a third-quarter 2025 loss of $1.75 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.32. In the year-ago quarter, the company posted a loss of $1.27 per share.Quarterly revenues rose 52% yea ...

Risk runs high, but so does the upside. Biotech investing thrives on bold bets and breakthrough data. On October 30, 2025, a wave of clinical-stage and commercial biopharma stocks surged to new 52-week highs, driven by breakthrough trial data, strategic deals, and earnings surprises. From obesity and CNS therapies to rare disease advances and acquisition drama, these moves reflect more than momentum; they signal conviction. Do you have these names on your watchlist? And more importantly, will they keep cli ...

Argenx shares rank No. 49 on the IBD 50 list of elite growth stocks. The stock has a strong IBD Digital Composite Rating of 98. The 1-99 score measures a stock's fundamental and technical metrics, pitting them against all other stocks. TRENDING: You Don't Have To Dig Far To Cash In On Rare Earths Insmed (INSM) stock catapulted higher while shares of Argenx (ARGX) creeped up Thursday after the top- rated biotech duo beat third-quarter expectations. Argenx, known for its blockbuster immunological-focused drug ...

Hong Kong conglomerate CK Hutchison has been studying a potential tie-up of its Italian telecom unit Wind Tre and the Italian operations of French telecoms group Iliad, three sources familiar with the... ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Insmed (INSM) came out with a quarterly loss of $1.75 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to a loss of $1.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -32.58%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.3 per share when it actually produced a loss of $1.7, delivering a ...

Insmed (NasdaqGS:INSM) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Company ParticipantsClara Dong - VP of Biotechnology Equity ResearchAsh Verma - Executive Director of Biopharmaceuticals Equity ResearchMartina Flammer - Chief Medical OfficerVamil Divan - Managing DirectorRoger Adsett - COOMaxwell Skor - VP of Biotechnology Equity ResearchBrandon Frith - Equity Research AssociateStephen Willey - Managing DirectorAndrea Newkirk - VP of Biotechnology Equity ResearchJason Zemansky - VP of Equity Researc ...

Insmed (NasdaqGS:INSM) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Company ParticipantsClara Dong - VP of Biotechnology Equity ResearchAsh Verma - Executive Director of Biopharmaceuticals Equity ResearchMartina Flammer - Chief Medical OfficerVamil Divan - Managing DirectorRoger Adsett - COOMaxwell Skor - VP of Biotechnology Equity ResearchBrandon Frith - Equity Research AssociateStephen Willey - Managing DirectorAndrea Newkirk - VP of Biotechnology Equity ResearchJason Zemansky - VP of Equity Researc ...

Insmed (NasdaqGS:INSM) Q3 2025 Earnings Call October 30, 2025 08:00 AM ET Speaker4Thank you for standing by. My name is Kayla and I will be your conference operator today. At this time I'd like to welcome everyone to the Insmed Incorporated third quarter 2025 financial results. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press STAR followed by the number ...